Capacitabine

Titlesort ascending Average Rating
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. 50.00%
Systems biology: a therapeutic target for tumor therapy. 86.67%
Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. 80.00%
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... 70.00%
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca.. 40.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. 80.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp 60.00%
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". 60.00%
Different metronomic treatment schedules 80.00%
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. 40.00%
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m 80.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. 40.00%
61 year old woman, Breast cancer with lymph, and lung metastasis 90.00%
To widen the setting of cancer patients who could benefit from metronomic capecitabine. 80.00%
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu 70.00%
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. 40.00%